AACR: Bay Area biotech bets on antibodies armed with immuno-stimulant to fight checkpoint-resistant cancers
The scientist behind the first prostate cancer vaccine Provenge — once celebrated as a historic breakthrough, but now a fading star — has devised a type …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
